Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI)-Reference-Cited by-同舟云学术

Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI)

Published:2021-10-05 Issue:1 Volume:27 Page:73-74
ISSN:1358-863X
Container-title:Vascular Medicine
language:en
Short-container-title:Vasc Med

Author:

Pichert Matthew D¹^ORCID,Smolderen Kim G¹²^ORCID,Castro-Dominguez Yulanka³^ORCID,Jelani Qurat-Ul-Ain¹^ORCID,Nagpal Sameer¹,Provance Jeremy B¹,Huang Jiaming⁴,Malik Ali O⁵⁶,Secemsky Eric A⁷^ORCID,Derbas Laith A⁸^ORCID,Mena-Hurtado Carlos I¹

Affiliation:

1. Vascular Medicine Outcomes Program at Yale University, Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA

2. Yale University, Department of Psychiatry, Yale University School of Medicine, New Haven, CT

3. Department of Cardiology, University Hospitals, Cleveland, OH

4. Dana Farber Cancer Institute, Boston, MA

5. Saint Luke’s Mid America Heart Institute, Kansas City, MI, USA

6. Department of Biomedical and Health Informatics, University of Missouri-Kansas City, Kansas City, MI, USA

7. Smith Center for Outcomes Research in Cardiology, Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, MA, USA

8. Division of Cardiology, Rush University, Chicago, IL, USA

Funder

Johnson&Johnson, Cardiva

Publisher

SAGE Publications

Subject

Cardiology and Cardiovascular Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/1358863X211043567

Reference5 articles.

1. Nationwide trends in drug-coated balloon and drug-eluting stent utilization in the femoropopliteal arteries

2. The LEVANT I (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) Trial for Femoropopliteal Revascularization